Alzamend Neuro enters ATM equity facility for up to $9.8M with Ascendiant Capital

Alzamend Neuro, Inc.

Entered Sales Agreement with Ascendiant Capital Markets for at-the-market issuance of common stock up to $9.8M.
Shares sold from time to time under effective shelf registration statement (File No. 333-273610) declared effective Aug 10, 2023.
Agent will use commercially reasonable efforts; Company sets parameters like number, time, and minimum price.
Either party may terminate agreement at any time upon written notice.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

Alzamend Neuro, Inc. entered into Sales Agreement with Ascendiant Capital Markets, LLC valued at up to approximately $9.8 million (effective 2023-09-08).

Action: entry
Agreement: atm program
Counterparty: Ascendiant Capital Markets, LLC
Value: up to approximately $9.8 million
Effective: 2023-09-08

Exact text from the filing

On September 8, 2023, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to approximately $9.8 million

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-23-012218

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.